What are the benefits of broadening drug policy beyond the misuse of drugs? Psilocybin’s proven to treat cluster migraines. Cannabis has been shown to treat Alzheimer’s and multiple mental health conditions. Is now the time to move to more evidence-based drug policy, or are these still hazardous substances that pose a risk to public health?
Chris Snowdon, Head of Lifestyle Economics, Institute of Economic Affairs (Chair)
Tara Austin, Consulting partner, Ogilvy Behavioural Science Practice
Crispin Blunt MP
Matthew Lesh, Head of Public Policy, Institute of Economic Affairs
Please view the live stream here